OKYO Highlights Urcosimod Data at Key Ophthalmology Conferences

Event summary

  • OKYO CEO Robert Dempsey will present at Eyecelerator on May 1, 2026, focusing on corneal and anterior segment diseases.
  • Chief Scientific Officer Raj Patil will present Phase 2 data on Urcosimod at ARVO’s Annual Meeting on May 5, 2026.
  • Urcosimod has received Fast Track designation from the FDA and is the first IND specifically for NCP treatment.
  • OKYO plans to initiate a 150-patient Phase 2b/3 study of Urcosimod for NCP in the first half of 2026.

The big picture

Neuropathic corneal pain represents a significant unmet medical need, with limited treatment options currently available. OKYO’s focus on Urcosimod, the first IND-approved therapy for NCP, positions them to capture a substantial share of a potentially large market. The success of the upcoming Phase 2b/3 trial will be critical in validating the drug’s efficacy and paving the way for regulatory approval and commercialization.

What we're watching

Clinical Adoption
The reception of the Urcosimod data at ARVO will be a key indicator of physician interest and potential adoption rates, influencing the speed of Phase 3 trial enrollment.
Regulatory Pathway
The FDA’s continued engagement with OKYO regarding Urcosimod’s Fast Track designation will be crucial, as any shift in their stance could impact the commercialization timeline.
Competitive Landscape
The presentation of Urcosimod’s efficacy data will likely draw increased scrutiny from competitors developing alternative NCP treatments, potentially accelerating their own development programs.